For patients & families
Your lymphocyte count is already on your blood work. Here is how to read it.
You do not need a new test, a specialist, or permission. You need the CBC with differential your team already orders, five minutes, and a question.
Step one
Find the line.
Open your most recent complete blood count (CBC) with differential in your patient portal or on the printed report. Look under the white blood cell section for a row labeled one of these:
- Lymphocytes, absolute or Absolute lymphocytes
- Lymphs # or Lymph, abs
- ALC
The absolute count is the one to use, not the percentage. A percentage can look normal while the actual number of cells is low, because it depends on how many neutrophils you have that day. Lymphocytes normally make up about 20–40% of white blood cells; the absolute count is the total white count multiplied by that percentage (Cleveland Clinic).
Watch the units.
Labs print the same number three ways. 1,000 cells/µL = 1.0 K/µL = 1.0 × 10⁹/L. So "0.53 K/µL" and "530 cells/µL" and "0.53 × 10⁹/L" are all the same result.
| Test | Result | Flag | Reference |
|---|---|---|---|
| WBC | 6.2 K/µL | 3.8–10.8 | |
| Neutrophils, absolute | 4.90 K/µL | 1.50–7.80 | |
| Lymphocytes, absolute | 0.53 K/µL | L | 0.85–3.90 |
| Lymphocytes, % | 8.5 % | L | 20–40 |
| Monocytes, absolute | 0.55 K/µL | 0.20–0.95 | |
| Eosinophils, absolute | 0.18 K/µL | 0.015–0.50 | |
| Basophils, absolute | 0.04 K/µL | 0.00–0.20 |
Illustrative report. The "L" flag means the result is below the lab's reference range. Reference ranges differ by laboratory; use the one printed on your own report.
Step two
Know what the number means.
For adults, most references put the normal range somewhere around 1,000 to 4,800 cells/µL (Cleveland Clinic); Mayo Clinic Laboratories prints 0.95–3.07 × 10⁹/L on its CBC report (Mayo Clinic Labs). Some commercial labs start the range at 850. A count below about 1,000 in an adult is called lymphopenia (Cleveland Clinic).
Oncologists grade side effects with a national scale called CTCAE. It has grades for a low lymphocyte count, and they are listed on the right (NCI CTCAE v5.0). Knowing your grade lets you ask a precise question: "My count is 530. That is grade 2. What does that mean for me?"
Two things the number is not. It is not a cancer diagnosis, and a single low value is not an emergency. Counts move with infections, steroids, stress and time of day. What matters is a low count that persists, especially after treatment, and whether anyone on your team is watching it.
| Grade | Lymphocyte count | In plain terms |
|---|---|---|
| Normal | Above your lab's lower limit (about 1,000) | Within the reference range printed on your report |
| 1 | Below normal, down to 800 | Mild. Worth writing down and rechecking |
| 2 | Below 800, down to 500 | Moderate. Beth's 525 was here |
| 3 | Below 500, down to 200 | Severe. Associated with roughly double the risk of death in chemoradiation studies |
| 4 | Below 200 | Life-threatening range |
Cells per microliter (cells/µL, same as cells/mm³). Source: NCI CTCAE v5.0, "Lymphocyte count decreased". Grade 3 risk from Grossman et al., 2015.
Why it drops
Treatment lowers it. Often for a long time.
Lymphocytes are among the most radiation-sensitive cells in the body, and many chemotherapy drugs deplete them too. In a study of 297 patients treated with chemotherapy and radiation for brain, pancreatic and lung cancers, 83% started with a normal count. Two months in, the median count had fallen 63%, from 1,481 to 560, and it stayed below 1,000 for the entire year of follow-up (Grossman et al., JNCCN 2015).
Radiation alone does much the same: across 52 published studies, counts fell to a median 24% of baseline by the end of radiotherapy and had recovered to only 55% of baseline a year later (Sandul et al., 2025).
The regimen Beth received, FOLFOX for colon cancer, is no exception. In 243 patients, 42.8% developed lymphopenia during FOLFOX, and those whose counts fell lowest had 3.5 times the risk of recurrence (Hong et al., BMC Cancer 2013).
Why that matters.
Neutrophils, the infection-fighting cells, are checked before every chemotherapy cycle because a crash is dangerous and there are drugs to prevent it. Lymphocytes are the cells that recognize and kill cancer cells. When they stay low after treatment:
- Severe treatment-related lymphopenia roughly doubled the risk of death in the 297-patient study above (HR 2.1) (Grossman 2015).
- Across 20 studies of radiation, severe lymphopenia raised the risk of death 65% after adjusting for other factors (Damen et al., 2021).
- Among 10,498 patients starting immunotherapy, those with a low count going in were 26% more likely to have died at two years (Ismail et al., 2026).
- Even in people without cancer, a count at or below 1,000 was linked to an 80% higher risk of death over the following years (Zidar et al., JAMA Network Open 2019).
The deaths in these studies were mostly from the cancer coming back, not from infection (Grossman 2011). That is the point: the count tracks the body's ability to fight the tumor.
There is now something to ask for
A low count used to mean "wait." It doesn't have to.
Anktiva, an IL-15 medicine, tells the body to make more of its own natural killer cells and T cells. It is FDA-approved for one bladder cancer and available through an FDA-authorized expanded-access program for lymphopenia after chemotherapy, radiation or immunotherapy (NCT06956547). Beth's count went from 525 to 1,400 after her first injection. Question five on the list below is where to start.
Step three
Seven questions for your oncologist.
Each one is grounded in a specific study, linked, so you can bring the paper if you want to. None of them asks your doctor to change your treatment. They ask your doctor to look.
- "What is my absolute lymphocyte count on my latest CBC, and is it below 1,000?"Lymphopenia is under 1,000 in adults; grade 2 below 800, grade 3 below 500 (Cleveland Clinic; CTCAE).
- "Was my count normal before treatment, and can we record it as my baseline?"83% of patients had a normal count before chemoradiation; it was the drop, not the starting point, that predicted survival (Grossman 2015).
- "Could my radiation or chemotherapy plan lower my lymphocytes, and are there ways to limit that?"In pancreatic cancer, keeping the mean spleen dose under 9 Gy has been proposed (Venkatesulu 2022).
- "If I am starting immunotherapy, does my count affect how well it may work?"Baseline count below 1,500 carried a 26% higher risk of death at two years in 10,498 matched patients (Ismail 2026).
- "How often will we recheck it during and after treatment?"Counts were only 55% recovered a year after radiotherapy (Sandul 2025); the median stayed under 1,000 for a year after chemoradiation (Grossman 2015).
- "If my count is low, should I take extra infection precautions?"In 98,344 people, lymphopenia raised the risk of any infection 41% and of dying from infection 70% (Warny 2018).
- "My count is below 1,000. Am I eligible for the Anktiva expanded-access program for lymphopenia, or a trial that restores lymphocytes?"IL-15 agonist therapy for lymphopenia is investigational. An FDA-authorized expanded-access protocol exists for adults with solid tumors that progressed after standard chemotherapy, immunotherapy or radiation (NCT06956547; Urology Times). How it works, and what the doctors say →
Someone who has been where you are
Beth found her number by accident. You do not have to.
After chemotherapy for Stage 3 colon cancer, Beth was told she was cancer-free. For two years she felt anything but, and did everything integrative and functional medicine offered. Nobody on her care team was treating her lymphocyte count, which fell to 525. She learned what the number meant from a television interview.
"They knew my name. They explained the science to me in plain language and never talked down to me. They watched my numbers as closely as I did."
Please read. This site is educational. It is not medical advice and does not replace your care team. Do not stop, start or change any treatment because of something you read here. The medicine discussed on this site, Anktiva, is FDA-approved only for one form of bladder cancer; its use to restore lymphocytes is investigational and available only through clinical trials or expanded access (FDA).